Finance

Beta
Ask
Lists
LLY:NYSE
Eli Lilly And Co
$1,102.08
+0.32%
(+3.51) 1D
$1,100.95
-0.10% (-1.13)
After hours
Closed: Jun 22, 4:05:42 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LLY...
Open
$1,112.24
High
$1,119.45
Low
$1,093.15
Mkt. cap
1.04T
Avg. vol.
3.20M
Volume
0.00
Dividend
0.63%
Quarterly dividend
$1.73
Ex-dividend date
May 15, 2026
P/E ratio
39.15
52-wk high
$1,182.73
52-wk low
$623.78
EPS
$28.15
Beta
0.53
Shares outstanding
941.74M
No. of employees
50K
Open
$1,112.24
High
$1,119.45
Low
$1,093.15
Mkt. cap
1.04T
Avg. vol.
3.20M
Volume
0.00
Dividend
0.63%
Quarterly dividend
$1.73
Ex-dividend date
May 15, 2026
P/E ratio
39.15
52-wk high
$1,182.73
52-wk low
$623.78
EPS
$28.15
Beta
0.53
Shares outstanding
941.74M
No. of employees
50K
News stories
From sources across the web
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Co
CEODavid A. Ricks
Employees50K
Founded1876
HeadquartersIndianapolis, Indiana, United States
SectorPharmaceutical industry
Websitelilly.com
Analyst Ratings
Based on 22 analysts giving stock ratings to LLY in the past 3 months
Strong Buy
Buy
20
Hold
2
Sell
0
12 month forecast
Based on 22 Wall Street analysts offering 12 month price targets for LLY in the last 3 months.
Highest
Current $1,102.08
$1,500.00 (+36.11%)
Average
$1,294.06 (+17.42%)
Lowest
$1,135.00 (+2.99%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Kerry Holford
Berenberg Bank
Hold
Maintained
$1,135.00
+3%
06/22/2026
Emily Field
Barclays
Buy
Maintained
$1,400.00
+27%
06/22/2026
Geoff Meacham
Citi
Buy
Maintained
$1,500.00
+36.1%
06/16/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$1,300.00
+18%
06/14/2026
Courtney Breen
Bernstein
Buy
Maintained
$1,300.00
+18%
06/09/2026
Akash Tewari
Jefferies
Buy
Maintained
$1,350.00
+22.5%
06/09/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
06/09/2026
Asad Haider
Goldman Sachs
Buy
Reiterated
$1,283.00
+16.4%
06/08/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$1,344.00
+22%
06/08/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
-
-
06/08/2026
David Risinger
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$1,280.00
+16.1%
05/27/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$1,251.00
+13.5%
05/26/2026
Alexandria Hammond
Wolfe Research
Buy
Maintained
$1,350.00
+22.5%
05/21/2026
Trung Huynh
RBC Capital
Buy
Maintained
$1,250.00
+13.4%
05/21/2026
James Shin
Deutsche Bank
Buy
Reiterated
$1,285.00
+16.6%
05/07/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$1,235.00
+12.1%
05/05/2026
Umer Raffat
Evercore ISI
Hold
Maintained
-
-
05/04/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$1,230.00
+11.6%
05/01/2026
Louise Chen
Scotiabank
Buy
Maintained
$1,300.00
+18%
04/28/2026
Michael Yee
UBS
Buy
Maintained
$1,250.00
+13.4%
04/20/2026
Steve Scala
TD Cowen
Buy
Maintained
$1,250.00
+13.4%
04/02/2026
Rajesh Kumar
HSBC
Sell
Maintained
$850.00
-22.9%
03/17/2026
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$8.55 / $6.79
+25.90%beat
Revenue / Est. (USD)
19.80B / 17.80B
+11.25%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
15.56B
17.60B
19.29B
19.80B
Cost of goods sold
2.45B
3.01B
3.37B
3.58B
Cost of revenue
2.45B
3.01B
3.37B
3.58B
Research and development expenses
3.34B
3.47B
3.80B
3.51B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.65B
2.63B
3.46B
2.93B
Operating expense
5.98B
6.09B
7.26B
6.44B
Total operating expenses
8.43B
9.10B
10.63B
10.02B
Operating income
7.13B
8.50B
8.66B
9.78B
Other non operating income
-101.00M
-9.10M
181.20M
170.00M
EBT including unusual items
6.78B
7.23B
8.27B
8.85B
EBT excluding unusual items
6.82B
8.21B
8.89B
9.71B
Income tax expense
1.12B
1.65B
1.63B
1.45B
Effective tax rate
16.47%
22.81%
19.70%
16.43%
Other operating expenses
-
-
-
-
Net income
5.66B
5.58B
6.64B
7.40B
Net profit margin
36.38%
31.72%
34.41%
37.36%
Earnings per share
6.31
7.02
7.54
8.55
Interest and investment income
40.00M
65.00M
672.40M
-
Interest expense
-249.00M
-179.60M
-153.30M
-332.00M
Net interest expenses
-209.00M
-114.60M
519.10M
-332.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.60B
8.97B
9.25B
10.29B
Gain or loss from assets sale
-
-
-180.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer